

## Table of Contents

<b>1. Introduction</b>		<b>1</b>
<b>1.1</b>	<i>Historical background</i>	<b>1</b>
<b>1.2</b>	<i>classifications of Herpesviruses</i>	<b>2</b>
<b>1.2.1</b>	<i>Alphaherpesvirinae</i>	<b>2</b>
<b>1.2.1.1</b>	<i>Genus Simplexvirus</i>	<b>2</b>
<b>1.2.1.2</b>	<i>Genus Varicellovirus</i>	<b>4</b>
<b>1.2.2</b>	<i>Betaherpesvirinae</i>	<b>4</b>
<b>1.2.3</b>	<i>Gammaherpesvirinae</i>	<b>4</b>
<b>1.2.3.1</b>	<i>Genus Lymphocryptovirus</i>	<b>5</b>
<b>1.2.3.2</b>	<i>Genus Rhadinovirus</i>	<b>5</b>
<b>1.3</b>	<i>Human cytomegalovirus</i>	<b>6</b>
<b>1.3.1</b>	<i>Structure of human cytomegalovirus</i>	<b>6</b>
<b>1.3.2</b>	<i>Glycoproteins</i>	<b>8</b>
<b>1.3.2.1</b>	<i>Major glycoprotein (gB; pUL55)</i>	<b>8</b>
<b>1.3.2.2</b>	<i>Glycoprotein H (gH, pUL75)</i>	<b>9</b>
<b>1.3.2.3</b>	<i>Glycoprotein L (gL, UL115)</i>	<b>9</b>
<b>1.3.2.4</b>	<i>UL16 glycoprotein</i>	<b>9</b>
<b>1.3.3</b>	<i>Tegument proteins</i>	<b>10</b>
<b>1.3.3.1</b>	<i>pp65</i>	<b>11</b>
<b>1.3.3.2</b>	<i>UL97 kinase</i>	<b>11</b>
<b>1.3.3.3</b>	<i>pp28 (ppUL99)</i>	<b>13</b>
<b>1.3.3.4</b>	<i>pp150 (ppUL32)</i>	<b>13</b>
<b>1.3.4</b>	<i>Capsid</i>	<b>14</b>
<b>1.4</b>	<i>Life cycle of HCMV</i>	<b>15</b>
<b>1.5</b>	<i>HCMV egress and assembly</i>	<b>18</b>
<b>1.6</b>	<i>Interaction of cellular kinases with HCMV</i>	<b>19</b>
<b>1.6.1</b>	<i>Serine threonine kinases</i>	<b>20</b>
<b>1.6.1.1</b>	<i>Staurosporine</i>	<b>21</b>
<b>1.7</b>	<i>Epidemiology of Human CMV</i>	<b>22</b>

	<i>Infection</i>	
<b>1.8</b>	<i>Diseases caused by HCMV</i>	<b>23</b>
<b>1.8.1</b>	<i>Cytomegalic inclusion disease (CID)</i>	<b>24</b>
<b>1.8.2</b>	<i>Asymptomatic congenital human cytomegalovirus</i>	<b>24</b>
<b>1.8.3</b>	<i>Perinatal infection</i>	<b>25</b>
<b>1.8.4</b>	<i>Human cytomegalovirus mononucleosis</i>	<b>25</b>
<b>1.8.5</b>	<i>Transfusion-acquired human cytomegalovirus infection</i>	<b>26</b>
<b>1.8.6</b>	<i>Human cytomegalovirus infections in immunocompromised patients</i>	<b>26</b>
<b>1.8.7</b>	<i>Other diseases caused by HCMV</i>	<b>26</b>
<b>1.9</b>	<i>HCMV antiviral drugs</i>	<b>27</b>
<b>1.10</b>	<i>Research significance</i>	<b>29</b>
<b>1.11</b>	<i>Objectives</i>	<b>30</b>
<b>2. Materials and Methods</b>		<b>31</b>
<b>2.1</b>	<i>Cell culture</i>	<b>31</b>
<b>2.1.1</b>	<i>Cell lines and media</i>	<b>31</b>
<b>2.1.2</b>	<i>Propagation and Passage of HFF Cell</i>	<b>32</b>
<b>2.1.3</b>	<i>Freezing and Thawing of HFF Cell</i>	<b>32</b>
<b>2.2</b>	<i>Viruses</i>	<b>33</b>
<b>2.2.1</b>	<i>Propagation of Viruses</i>	<b>34</b>
<b>2.2.2</b>	<i>Viral Titration and Plaque Assay</i>	<b>35</b>
<b>2.2.3</b>	<i>Viral infection assay</i>	<b>36</b>
<b>2.3</b>	<i>Immunofluorescence (IF)</i>	<b>38</b>
<b>2.4</b>	<i>Monoclonal, polyclonal antibodies and fluorescing markers</i>	<b>39</b>
<b>2.5</b>	<i>Fluorescence Image capturing</i>	<b>40</b>
<b>2.6</b>	<i>Cell lysis for protein extraction</i>	<b>41</b>
<b>2.7</b>	<i>Western Blot analysis (WB)</i>	<b>42</b>
<b>2.7.1</b>	<i>Preparation of the polyacrylamide</i>	<b>42</b>